Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
Clinical trial NCT06434363 · RECRUITING
Trial details
- NCT number
- NCT06434363
- Sponsor
- M.D. Anderson Cancer Center
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-07-31
- Primary completion
- 2028-12-31
- Enrollment
- 47
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.